About UmanDiagnostics
UmanDiagnostics is a Healthcare company based in Umea (Sweden) founded in 2006, and was acquired by Quanterix in June 2019. Rapid ELISA tests for MS, ALS, and PD are developed. UmanDiagnostics offers products and services including NF-Lightâ„¢ Serum ELISA assay, NF-Lightâ„¢ CSF ELISA assays, and anti-NF-Light Antibodies. Its focus areas include Life Sciences, Neurology, In-Vitro Diagnostics and Neurodegenerative. Its legal entity is UmanDiagnostics AB.
Company details
UmanDiagnostics was founded in 2006 in Umea, Sweden, within the biotechnology sector focused on neurological diagnostics. Tools for early detection, treatment efficacy measurement, and disease progression monitoring are developed and marketed, with emphasis on white matter disorders such as multiple sclerosis and amyotrophic lateral sclerosis. The primary product, NF-light, is an ELISA assay enabling neurofilament light quantification in cerebrospinal fluid within three hours.
- Headquarters Umea, Sweden
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website umandiagnostics.com
- Social LinkedIn
- Acquired by Quanterix (Jun 2019)
- Legal Name Umandiagnostics Ab
Products & Services of UmanDiagnostics
UmanDiagnostics offers a comprehensive portfolio of products and services, including NF-Light™ Serum ELISA assay, NF-Light™ CSF ELISA assays, and anti-NF-Light Antibodies.
Quantifies Neurofilament light in serum for neurological injury detection.
Measures NF-L in CSF samples to detect neuronal damage.
Provides monoclonal antibodies for NF-L research applications.
Investors in UmanDiagnostics
UmanDiagnostics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Quanterix.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Assay kits for ultra-sensitive biomarker detection are developed. | 2007 | quanterix.com | Cambridge, United States |
Investor details for UmanDiagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of UmanDiagnostics
2 dated milestones of UmanDiagnostics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded UmanDiagnostics is founded.
- Exit Acquired by Quanterix.
Web traffic of UmanDiagnostics
The website of UmanDiagnostics (umandiagnostics.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▼ 15.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Umandiagnostics
Complete news archive for UmanDiagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UmanDiagnostics
UmanDiagnostics was founded in 2006.
UmanDiagnostics is headquartered in Umea, Sweden.
UmanDiagnostics was founded in 2006 in Umea, Sweden, within the biotechnology sector focused on neurological diagnostics. Tools for early detection, treatment efficacy measurement, and disease progression monitoring are developed and marketed, with emphasis on white matter disorders such as multiple sclerosis and amyotrophic lateral sclerosis. The primary product, NF-light, is an ELISA assay enabling neurofilament light quantification in cerebrospinal fluid within three hours.
UmanDiagnostics offers NF-Lightâ„¢ Serum ELISA assay, NF-Lightâ„¢ CSF ELISA assays, and anti-NF-Light Antibodies.
UmanDiagnostics has 1 investor. Key investors include Quanterix.
UmanDiagnostics operates through Umandiagnostics Ab.
Yes. UmanDiagnostics was acquired by Quanterix in June 2019.